Effect of Compound 21, a Selective Angiotensin II Type 2 Receptor Agonist, in a Murine Xenograft Model of Dupuytren Disease.
- Jessica Chisholm,
- Alison J Gareau,
- Stephanie Byun,
- Justin L Paletz,
- David Tang,
- Jason Williams,
- Terry LeVatte,
- Michael Bezuhly
Plast Reconstr Surg 2017 Nov;140(5):686e-696e
Halifax, Nova Scotia, Canada From the Department of Microbiology and Immunology and the Department of Surgery, Division of Plastic and Reconstructive Surgery, Dalhousie University; and the Izaak Walton Killam Health Centre.
Background: Although surgical excision and intralesional collagenase injection are mainstays in Dupuytren disease treatment, no effective medical therapy exists for recurrent disease. Compound 21, a selective agonist of the angiotensin II type 2 receptor, has been shown to protect against fibrosis in models of myocardial infarction and stroke. The authors investigated the potential use of compound 21 in the treatment of Dupuytren disease. Read More